A major global analysis has revealed the profound impact of cannabis commercialisation on international public health. Historically, debates around drug policy have focused heavily on whether to maintain strict prohibition or remove criminal penalties. However, this new research indicates that the mechanism of legalisation matters far more than the simple removal of criminal penalties. Removing penalties for possessing cannabis for personal use does not increase levels of use. By contrast, opening the door to commercial, for-profit markets triggers a sharp rise in cannabis addiction, daily use, and psychiatric hospital admissions.

The comprehensive study was published in The Lancet Psychiatry and led by mental health and addiction experts at the University of Bath. An international team of researchers from the Americas, Europe, Africa, Australia, New Zealand, and Asia collaborated on the project. Researchers examined how evolving international policies between 2000 and 2025 impact public health outcomes. The findings highlight a critical distinction between removing criminal penalties for personal possession and allowing commercial interests to drive drug consumption. When public health is set aside in favour of corporate growth, the societal consequences accumulate rapidly.

Cannabis Commercialisation vs. Tightly Controlled Regulation

Decriminalisation or tightly controlled legalisation shows little evidence of increased drug use among the general population. The study points to Uruguay as a primary example of a highly regulated framework. In Uruguay, adults access a restricted range of low potency products via state licensed pharmacies. Citizens can also form cannabis social clubs or grow a limited number of plants at home. Because the state limits product potency and bans aggressive corporate marketing, public health metrics have remained stable.

However, the story changes entirely when commercial markets take over. In Canada and various US states, cannabis legalisation has paved the way for massive for-profit industries. This structural shift has driven up product potency, sales, and total consumption. Co-author Professor Tom Freeman noted that the emergence of a for-profit market prioritises commercial interests over public health. This corporate trend closely mirrors the historical tactics of the alcohol and tobacco industries. These industries historically expanded their reach by engineering more addictive products and lobbying against health regulations.

The public health consequences of this shift are stark. In the United States, there are now more daily consumers of cannabis than daily consumers of alcohol. This rise in consumption has been accompanied by a surge in cannabis addiction. Individuals frequently struggle to stop using the drug despite negative impacts on their daily lives, employment, and relationships. Furthermore, researchers tracked a notable increase in hospital admissions for psychosis. This severe mental health condition frequently occurs alongside cannabis addiction, complicating treatment protocols.

Implications for Future Drug Policy

The research comes at a pivotal time for UK drug policy. Currently, cannabis is a Class B drug under the Misuse of Drugs Act. Possession carries a maximum penalty of five years in prison, an unlimited fine, or both. However, recent proposals have advocated for decriminalising personal possession. The 2025 London Drugs Commission report proposed this to shift the focus from the criminal justice system toward healthcare. The commission also noted that decriminalisation could address the disproportionate level of policing found in Black communities.

The global data suggests that removing criminal penalties protects individuals from the harms of criminalisation without driving up drug use. Conversely, full cannabis commercialisation creates an entirely new set of health crises. Aggressive marketing, increased availability, and higher product strength inherently elevate the risk of long-term dependency. When retail dispensaries compete for market share, they naturally introduce stronger concentrates and edibles to attract consumers. This commercial drive leaves vulnerable populations exposed to much higher doses of psychoactive chemicals than nature intended.

The Risks of Medical Cannabis and Mental Health

The analysis also raised flags regarding poorly regulated access to medical cannabis. The researchers warned that prescribing cannabinoids without robust evidence of safety and effectiveness can increase public health risks. Currently, the Advisory Council on the Misuse of Drugs is reviewing evidence on the impact of the UK legalisation of medical cannabis. They are assessing whether the policy achieved its desired aims or caused unintended consequences.

A synthesis of 54 clinical trials evaluating medical cannabinoids for psychiatric disorders found little strong evidence of their effectiveness. While minor benefits were noted for insomnia, tics, and cannabis withdrawal, the products showed no meaningful effect for anxiety, PTSD, or psychosis. They actually increased cocaine cravings in individuals with cocaine use disorder. There were no trials available regarding the treatment of depression, raising further questions about widespread medical claims.

The second review in the collection found evidence that daily cannabis use can act with other risk factors to increase the risk of psychosis. However, its role in depression, anxiety, and suicidal thoughts remains less clear. The data underscores the need for objective, non-commercial research into how these substances affect the human brain over extended periods.

As global policies continue to evolve, experts urge policymakers to approach legalisation with extreme caution. The pursuit of profit from cannabis commercialisation inevitably fuels cannabis addiction and broader mental health challenges. Public health frameworks must prioritize prevention education and early intervention over industry expansion. If corporate entities are permitted to dictate the terms of drug policy, public healthcare systems will bear the financial and structural burden of treating the resulting dependency crises.

Source: dbrecoveryresources